<DOC>
	<DOCNO>NCT00866398</DOCNO>
	<brief_summary>Since advent coronary stent , in-stent restenosis proven major limitation interventional cardiology , occur many 30 % patient . Drug-eluting stent specifically design prevent problem in-stent restenosis . They consist selective anti-proliferative drug , sirolimus , controlled-release polymer , closed-cell stent delivery platform . Upon placement , sirolimus elutes vessel wall stop process neointimal hyperplasia , thereby significantly reduce incidence in-stent restenosis . The study `` Economic Evaluation German Drug-Eluting Stent Registry '' examine cost-effectiveness drug-eluting stent compare bare-metal stent ( BMS ) patient coronary stenosis . The goal study examine whether guideline-supported implantation SES , despite high initial cost , improve quality economic outcome treatment patient coronary stenosis . Secondarily , study evaluate patient quality life , impairment daily activity , re-intervention rate .</brief_summary>
	<brief_title>Economic Evaluation German Drug-Eluting Stent Registry</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>Indication coronary stent implantation Additional inclusion criterion BMS cohort : Acute Coronary Syndrome Diabetes Mellitus Previous Percutaneous Coronary Intervention/Coronary Artery Bypass Graft 3Vessel Disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>coronary heart disease</keyword>
	<keyword>chd</keyword>
	<keyword>stent</keyword>
</DOC>